News wire
U.S. Food and Drug Administration
Stories that name U.S. Food and Drug Administration.
Source check 6 min ago · Newest item 7 hr ago · 1,441 stories this week · 87 of 90 publishers answering · Browse publishers · RSS feed
Filter stories
Saved on this browser
U.S. Food and Drug Administration
Friday, November 20
FDA Petitioned to Permit D-Tagatose in Dietary Fiber Declaration
FDA Proposes Rule to Permit NAC in Dietary Supplements
Thursday, November 19
Hemp Guardrails Act: A Proposed Federal Framework Ahead of December 11
Tuesday, November 17
K&L Gates Hires Peterson Wilmarth Drug Law Lawyer In DC
State Legislation Update: New York GRAS Bill Heads to Governor While 2027 Prefiling Begins
Monday, November 16
Doctor Seeks J&J FDA Records In Talc Libel Suit
FDA Takes Action Against International Prescription
Ozempic and Vision Loss: What the FDA’s New NAION Warning Means in Illinois
On November 9, 2026, the FDA ordered every company that sells a GLP-1 drug to add a new warning to its label: a possible increased risk of NAION, a rare eye condition that can cause sudden and sometimes permanent vision loss. The order covers Ozempic, Wegovy, Mounjaro, Zepbound and every other GLP-1 on the market.... Continue Reading
Some Hemp Is Now Illegal, the Feds Just Won’t Tell Us Which Hemp: A New Litigation Frontier?
Friday, November 13
Illinois Medicaid Filled Nearly 1 Million Prescriptions for Leading GLP-1 Drugs Before the FDA’s Vision Loss Warning
Illinois Medicaid paid for 993,119 prescriptions for nine leading GLP-1 drugs between 2022 and 2025, at a gross cost of $1.1 billion. Every one was filled before November 9, 2026, when the FDA ordered manufacturers to add a warning about a rare form of permanent vision loss called NAION. Ankin Law analyzed four years of... Continue Reading
Supplement Makers Say FDA Added Illegal Label Review
FDA Issues 2026 Retail Food Standards
Thursday, November 12
Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen
FOR IMMEDIATE RELEASE – November 12, 2026 - Tampa, Florida. Game Changer Products LLC is voluntarily recalling all lots of 10 Day Forecast capsules to the consumer level. FDA analysis has found the product to be tainted with sildenafil and acetaminophen. Sildenafil is an active ingredient in an FDA
FDA’s Proposed GRAS Rule: Why Companies Should Prepare Now
FDA Warns Ozempic, Wegovy, and Other GLP-1 Drugs May Cause Permanent Vision Loss
The FDA warns Ozempic, Wegovy, and other GLP-1 drugs may cause permanent vision loss. It is requiring new safety warnings on the popular weight loss and diabetes medications after finding evidence of an increased risk of a serious eye condition that can cause blindness. The November 9, 2026, announcement affects medications including Ozempic, Wegovy, Mounjaro,... Continue Reading
Wednesday, November 11
FDA Orders New GLP-1 Risk Warnings Over Vision Loss
Read at Law360 Product Liability 3 publishers · 3 reports
Tandem recalls Mobi insulin pump, reports 230 adverse events
Tuesday, November 10
Pharma Co. Investors Ink $4M Deal In FDA Hurdle Suit
FDA Revokes Authorizations of Substances for Use in Color Additive Production
FDA Updates Food Allergen Labeling FAQs
Monday, November 9
Compass Submits Psilocybin Depression Drug To FDA
FDA Requires New Vision Loss Warnings for Ozempic, Wegovy and Other GLP-1s Over NAION Risk
Boston Scientific Spinal Cord Stimulator Lawsuits
Read at Lawsuit Information Center 2 publishers · 2 reports
MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
Friday, November 6
MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy: FDA Safety Communication
Medical Devices; Ear, Nose, and Throat Devices; Classification of the External Mechanical Stimulator for the Relief of Congestion
The Food and Drug Administration (FDA) is classifying the external mechanical stimulator for the relief of congestion into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the external mechanical stimulator for the relief of congestion. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to…
Thursday, November 5
Lawsuit Alleges Cartiva Synthetic Cartilage Implant Failure Led to Additional Toe Surgery
FDA’s Draft Guidance on Demonstrating Substantial Evidence of Effectiveness
Medical Devices; Hematology and Pathology Devices; Classification of the Digital Cervical Cytology Slide Imaging System With Artificial Intelligence Algorithm
The Food and Drug Administration (FDA) is classifying the digital cervical cytology slide imaging system with artificial intelligence algorithm into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the digital cervical cytology slide imaging system with artificial intelligence algorithm. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We…
Connect the news to your market.
Research the firms, offices and conference relationships behind the headlines.